erlotinib hydrochloride has been researched along with uric acid in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (uric acid) | Trials (uric acid) | Recent Studies (post-2010) (uric acid) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 27,980 | 1,717 | 9,982 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | uric acid (IC50) |
|---|---|---|---|
| Solute carrier family 2, facilitated glucose transporter member 9 | Homo sapiens (human) | 300 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilici, A; Dagel, T; Dilege, S; Ertuglu, LA; Erus, S; Kanbay, M; Kapdağlı, M; Mandel, NM; Ozdogan, E; Selcukbiricik, F; Tanju, S; Tural, D | 1 |
1 other study(ies) available for erlotinib hydrochloride and uric acid
| Article | Year |
|---|---|
Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |